Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Intellia Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Intellia Therapeutics, Inc.’s stock price such as:

• Intellia Therapeutics, Inc.’s current stock price and volume
• Why Intellia Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for NTLA from analysts
• NTLA’s stock price momentum as measured by its relative strength

About Intellia Therapeutics, Inc. (NTLA)

Before we jump into Intellia Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Want to learn more about Intellia Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Intellia Therapeutics, Inc..

Intellia Therapeutics, Inc.’s Stock Price as of Market Close

As of December 23, 2025, 4:00 PM, CST, Intellia Therapeutics, Inc.’s stock price was $9.420.

Intellia Therapeutics, Inc. is down 2.89% from its previous closing price of $9.700.

During the last market session, Intellia Therapeutics, Inc.’s stock traded between $9.340 and $9.560. Currently, there are approximately 110.19 million shares outstanding for Intellia Therapeutics, Inc..

Intellia Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Intellia Therapeutics, Inc. Stock Price History

Intellia Therapeutics, Inc.’s (NTLA) price is currently up 4.78% so far this month.

During the month of December, Intellia Therapeutics, Inc.’s stock price has reached a high of $9.950 and a low of $8.085.

Over the last year, Intellia Therapeutics, Inc. has hit prices as high as $28.250 and as low as $5.900. Year to date, Intellia Therapeutics, Inc.’s stock is down 19.21%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Intellia Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 23, 2025, there were 2 analysts who downgraded Intellia Therapeutics, Inc.’s stock and 8 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Intellia Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Intellia Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Intellia Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Intellia Therapeutics, Inc. (NTLA) by visiting AAII Stock Evaluator.

Relative Price Strength of Intellia Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 23, 2025, Intellia Therapeutics, Inc. has a weighted four-quarter relative price strength of -9.36%, which translates to a Momentum Score of 24 and is considered to be Weak.

Want to learn more about how Intellia Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Intellia Therapeutics, Inc. Stock Price: Bottom Line

As of December 23, 2025, Intellia Therapeutics, Inc.’s stock price is $9.420, which is down 2.89% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Intellia Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.